Delving into the Latest Updates on S-100 protein antibody(Materia Medica Holding) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Tenoten

Target-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Anxiety Disorders

Inactive Indication

Brain InjuriesLearning Disabilities

Originator Organization

OOO NPF Materia Medica Holding

Active Organization

OOO NPF Materia Medica Holding

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

The purposes of this study are:
To further examine the efficacy and safety of Tenoten® in the treatment of anxiety in patients with somatoform, stress-related and other neurotic disorders.
To compare the efficacy of two dosing regimens of Tenoten® (4 tablets daily vs.8 tablets daily, both for 12 weeks) in the treatment of anxiety in patients with somatoform, stress-related and other neurotic disorders.

Start Date08 Feb 2017

Sponsor / Collaborator

OOO NPF Materia Medica Holding

NCT03159611 / CompletedPhase 3

Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Tenoten for Children Liquid Dosage Form Therapy in Infants With Sequelae of Perinatal Brain Injury

Purpose of the study:
To assess the clinical efficacy of Tenoten for children liquid dosage form therapy (10 oral drops per day for 12 weeks) in Infants with Sequelae of Perinatal Brain Injury (mild-to-moderate cerebral hypoxia-ischaemia and/or mild-to-moderate intracranial haemorrhage).
To assess the safety of Tenoten for children liquid dosage form therapy (10 oral drops per day for 12 weeks) in Infants with Sequelae of Perinatal Brain Injury (mild-to-moderate cerebral hypoxia-ischaemia and/or mild-to-moderate intracranial haemorrhage).

Start Date19 Feb 2016

Sponsor / Collaborator

OOO NPF Materia Medica Holding

NCT03159104 / CompletedPhase 3

Multicenter Double-blind Placebo-Controlled Randomized Clinical Trial of Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children

Purpose of the study:
• To evaluate efficacy and safety of Tenoten for children in the treatment of specific developmental disorders of scholastic skills in children.

Start Date25 Aug 2015

Sponsor / Collaborator

OOO NPF Materia Medica Holding

100 Clinical Results associated with S-100 protein antibody(Materia Medica Holding)

Login to view more data

100 Translational Medicine associated with S-100 protein antibody(Materia Medica Holding)

Login to view more data

100 Patents (Medical) associated with S-100 protein antibody(Materia Medica Holding)

Login to view more data

67

Literatures (Medical) associated with S-100 protein antibody(Materia Medica Holding)

23 Jan 2024·Blood Advances

Protein S antibody as an adjunct therapy for hemophilia B

Article

Author: Chatterjee, Sabyasachi ; Velez, Maria C. ; Janbain, Maissaa ; Pierre, Aliyah ; Majumder, Rinku ; Dorsey, Adrianne W. ; Polania-Villanueva, Diana ; Paysse, Ashley L. ; Kumar, Narender ; Rudra, Pratyadipta ; Wilson, Hope P. ; Cooley, Brian C.

AbstractHemophilia B (HB) is caused by an inherited deficiency of plasma coagulation factor IX (FIX). Approximately 60% of pediatric patients with HB possess a severe form of FIX deficiency (<1% FIX activity). Treatment typically requires replacement therapy through the administration of FIX. However, exogenous FIX has a limited functional half-life, and the natural anticoagulant protein S (PS) inhibits activated FIX (FIXa). PS ultimately limits thrombin formation, which limits plasma coagulation. This regulation of FIXa activity by PS led us to test whether inhibiting PS would extend the functional half-life of FIX and thereby prolong FIX-based HB therapy. We assayed clotting times and thrombin generation to measure the efficacy of a PS antibody for increasing FIX activity in commercially obtained plasma and plasma from pediatric patients with HB. We included 11 pediatric patients who lacked additional comorbidities and coagulopathies. In vivo, we assessed thrombus formation in HB mice in the presence of the FIXa ± PS antibody. We found an accelerated rate of clotting in the presence of PS antibody. Similarly, the peak thrombin formed was significantly greater in the presence of the PS antibody, even in plasma from patients with severe HB. Furthermore, HB mice injected with PS antibody and FIX had a 4.5-fold higher accumulation of fibrin at the thrombus induction site compared with mice injected with FIX alone. Our findings imply that a PS antibody would be a valuable adjunct to increase the effectiveness of FIX replacement therapy in pediatric patients who have mild, moderate, and severe HB.

01 Jan 2024·S.S. Korsakov Journal of Neurology and Psychiatry

Anxiety disorders as comorbid conditions in neuropsychiatric diseases in children

Review

Author: Zavadenko, N N ; Zavadenko, A N ; Shypilova, E M ; Nesterovskiy, Yu E

The variants of heterotypic comorbidity of anxiety disorders (AD) with attention deficit hyperactivity disorder, autism spectrum disorders, speech and language development disorders, specific learning disabilities (dyslexia, dysgraphia, dyscalculia), migraine, tension type headache in children and adolescents are discussed. In cases of heterotypic comorbidity the patients with AD referrals to specialists may be primarily associated with their emotional problems. Meanwhile, the comorbidity of AD with these diseases leads to a deterioration of their clinical manifestations and a worsening of the prognosis, and anxiety symptoms often not only persist, but also increase with age. It should be borne in mind that AD in children with neurodevelopmental disorders contribute to a decrease in the quality of life, academic failure, have a negative impact on peer relationships and the family environment, and in young adulthood, patients have an increased risk of depression and substance abuse. Therefore, early intervention and a comprehensive therapeutic approach with a dynamic assessment of the patient's condition are becoming important. When choosing pharmacotherapy, it is advisable to choose medictions that have a complex effect on the pathogenetic mechanisms of the underlying disease and concomitant AD, which include Tenoten for children.

01 Jan 2021·Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova

Neurodevelopmental disorders in children and the possibilities of their pharmacotherapy

Article

Author: Fateeva, V V ; Zavadenko, N N ; Zavadenko, A N ; Suvorinova, N Yu

Neurodevelopmental disorders (NDD) are characterized by disturbances of the formation of cognitive functions, communication skills, behavior characteristics and/or motor skills, which are caused by abnormalities in the course of the processes of neuroontogenesis. In the clinical practice of a pediatric neurologist and pediatrician, a significant part consists of patients with NDD without a general decrease in intelligence, primarily with speech development disorders, attention deficit hyperactivity disorder (ADHD), specific learning disorders (dyslexia, dysgraphia, dyscalculia). NDD represent a heterogeneous group of diseases, having multifactorial origin and a neurobiological nature, which are caused by genetic mechanisms and early (perinatal) brain damage. Among children with NDD, there is a higher occurrence of anxiety disorders compared to their peers. With NDD, early intervention is indicated, and its positive effect is possible during the period when the brain is most plastic and capable of changes. The published results of multicenter, double-blind, placebo-controlled, randomized clinical trials of pharmacotherapy with the medication "Tenoten for children" for ADHD, specific learning disorders, anxiety disorders and the consequences of perinatal damage to the central nervous system are reviewed.

100 Deals associated with S-100 protein antibody(Materia Medica Holding)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anxiety Disorders	RU	OOO NPF Materia Medica Holding	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain Injuries	Discovery	RU	OOO NPF Materia Medica Holding	19 Feb 2016
Learning Disabilities	Discovery	RU	OOO NPF Materia Medica Holding	25 Aug 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03159104 (CTgov)	Phase 3	Learning Disabilities	240	Tenoten for children (Tenoten for Children)	vomknmjmtq(rikzalfmsr) = rsnxkqglpe fdcmmctcfk (zztzpynspr, uuhpltzmmc - fniheexqsc) View more	-	21 Aug 2023
				Placebo (Placebo)	vomknmjmtq(rikzalfmsr) = magqnbdwfi fdcmmctcfk (zztzpynspr, mookcmytth - hivfpvkcer) View more
NCT03036293 (CTgov)	Phase 4	Anxiety Disorders	390	Tenoten (Tenoten, 2 Tablets Twice Daily (4 Tablets/Day))	cbuxppdlsn(aeyqauhrkl) = lxdlldakte bgbtzzlqqu (auxtruacsp, xsvftnmzem - oxbuzzeswe) View more	-	31 Dec 2020
				Tenoten (Tenoten, 2 Tablets 4 Times Daily (8 Tablets/Day))	cbuxppdlsn(aeyqauhrkl) = unsnrvyayz bgbtzzlqqu (auxtruacsp, mefarvppex - ndowwgohvo) View more
NCT03159611 (CTgov)	Phase 3	Brain Injuries	182	Tenoten for children (Tenoten for Children)	udxegenprm(ztqdwdrrnf) = zazcidlcqu rdwyyzyxvk (geyvwgaebj, hqldjovtcq - viovqbbwsn) View more	-	08 Apr 2019
				Placebo (Placebo)	udxegenprm(ztqdwdrrnf) = gbioyeltdu rdwyyzyxvk (geyvwgaebj, mqerucubcf - ozumhpihks) View more